New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants

Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29 patients (17 patients received dabigatran and 12...

ver descrição completa

Detalhes bibliográficos

Principais autores:	K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Столичная издательская компания 2020-11-01
coleção:	Рациональная фармакотерапия в кардиологии
Assuntos:	dabigatran rivaroxaban pharmacogenetics direct oral anticoagulants sequencing personalized medicine
Acesso em linha:	https://www.rpcardio.online/jour/article/view/2288
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!